New Leadership in Clinical Research for the VCCC’s Next Chapter
- Victorian Comprehensive Cancer Centre
Dr Mark Buzza appointed Head of Clinical Research Programs of the Victorian Comprehensive Cancer Centre alliance
As the VCCC moves towards an exciting new chapter in our growth and development, we are very pleased to announce the appointment of Dr Mark Buzza as Head of Clinical Research Programs. Mark will lead the strategic development and operational delivery of the VCCC clinical research programs portfolio.
Mark has a PhD in molecular medicine, an Executive MBA and has a background in biotech and big pharma and has led numerous global pre-clinical and clinical drug development programs. He also has a depth of experience in not-for-profit and health services sectors and has an international reputation as an advisor to the global Digital Health collaboration platform HealthXL and as Scientific Advisory Board member of the PIONEER consortium, the European network for excellence in big data in prostate cancer. Most recently Mark was the Global Director of Prostate Cancer Biomedical Research Programs at Movember where he was responsible for overseeing a diverse $370 million research portfolio comprising over 620 projects across 21 countries.
Enhancing the impact of Victoria's clinical cancer research
Mark’s strategic insights and experience will make a significant contribution to our efforts to enhance the impact of Victoria’s cutting-edge clinical cancer research. Bringing a strong track record in both the medical research sector and managing large scale global collaborations, Mark is well placed to lead current and future initiatives at organisation and clinical research portfolio levels. Mark will work in close collaboration with VCCC Clinical Trials Development Lead Professor Mark Rosenthal, supported by a team of program managers and contributors from across VCCC members and partners.
Executive Director of the VCCC alliance, Professor Grant McArthur, said Mark brings a set of skills that will be ideally suited to the VCCC’s collaborative approach. “Mark has a wealth of experience in a wide range of clinical research and his most recent role has been with an organisation that has been a true innovator in collective impact. I believe he will be a fantastic addition to the team and to achieving our vision for the VCCC.”
Proven capacity for leading innovation in clinical trials
Mark’s significant experience and proven capacity for leading innovation in clinical trials will also complement the VCCC’s collaborations with the Australian Clinical Trials Alliance; the Melbourne Academic Centre for Health; the Victorian Regional Trials Network and other national and Victorian cooperative clinical trials groups.
“After many years of collaborating with key oncology stakeholders within the wider VCCC alliance, I am delighted to now be joining the VCCC as part of the executive team,” commented Mark. “I very much look forward to working with the team and key partners within and outside the alliance so that we can collectively make a positive difference to the lives of the people with cancer that we all serve.”
Mark will commence the role on Tuesday 14 July 2020.